Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation and Depletion (2021 - 2024)

ARS Pharmaceuticals' Depreciation and Depletion history spans 4 years, with the latest figure at $29000.0 for Q4 2024.

  • For Q4 2024, Depreciation and Depletion rose 141.67% year-over-year to $29000.0; the TTM value through Dec 2024 reached $79000.0, up 8.22%, while the annual FY2024 figure was $79000.0, 8.22% up from the prior year.
  • Depreciation and Depletion for Q4 2024 was $29000.0 at ARS Pharmaceuticals, up from $21000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $209000.0 in Q2 2021 and bottomed at -$37000.0 in Q2 2022.
  • The 4-year median for Depreciation and Depletion is $20500.0 (2023), against an average of $61625.0.
  • The largest annual shift saw Depreciation and Depletion crashed 117.7% in 2022 before it soared 200.0% in 2023.
  • A 4-year view of Depreciation and Depletion shows it stood at $204000.0 in 2021, then crashed by 93.14% to $14000.0 in 2022, then dropped by 14.29% to $12000.0 in 2023, then soared by 141.67% to $29000.0 in 2024.
  • Per Business Quant, the three most recent readings for SPRY's Depreciation and Depletion are $29000.0 (Q4 2024), $21000.0 (Q3 2024), and $18000.0 (Q2 2024).